Open an account

Stereotaxis

STXS · NYSE American

$0.9983−$0.0117 (−1.16%)TodayMarket closed ·
Prev close $1.01

About STXS

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The company is headquartered in St. Louis, Missouri and currently employs 131 full-time employees. The company went IPO on 2004-08-12. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.

Employees
131
Headquarters
St. Louis, Missouri
Listed
Aug 12, 2004
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
stereotaxis.com

STXS key statistics

Market cap
100.03M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
567.54K
Volume
637.38K
Open price
$1.01
High today
$1.03
Low today
$0.98
52 Week high
$3.15
52 Week low
$0.95

Stereotaxis (STXS) at a glance

As of Oct 20, 2026, Stereotaxis (STXS) shares are priced at $0.9983, giving the company a market cap of 100.03M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.98 and $1.03. The current price is 1.9% above the day's low and 3.1% below its high.

Volume so far is 637.38K shares, in line with the average of 567.54K shares a day.

Over the past year Stereotaxis has ranged from $0.95 to $3.15, and now sits 2% of the way up that range.

Stereotaxis met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.05 per share against an estimate of -$0.051.

The average analyst price target is $3.06, 206.5% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $3.06
Low
$3.03
Now
$0.9983
High
$3.15

STXS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 10.5% on average.

  1. Q3 FY24: reported -$0.08 per share against an estimate of -$0.0536
  2. Q4 FY24: reported -$0.09 per share against an estimate of -$0.0663
  3. Q1 FY25: reported -$0.07 per share against an estimate of -$0.074
  4. Q2 FY25: reported -$0.05 per share against an estimate of -$0.0663
  5. Q3 FY25: reported -$0.07 per share against an estimate of -$0.0612
  6. Q4 FY25: reported -$0.06 per share against an estimate of -$0.0667
  7. Q1 FY26: reported -$0.06 per share against an estimate of -$0.0502
  8. Q2 FY26: reported -$0.05 per share against an estimate of -$0.051

STXS news

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Preview: Stereotaxis's Earnings

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • A Look at Stereotaxis's Upcoming Earnings Report

  • Triveni Kothapalli

    New Robotic System Promises Faster, Safer Care For Arrhythmia Patients

Similar companies

Companies in the same industry as Stereotaxis

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.